1. Referral Patterns From Primary Care Clinicians to Specialists Among People With Cognitive Impairment Disorders, including Alzheimer's Disease.
- Author
-
Mearns, Elizabeth S, Patel, Anisha M, Jinnett, Kimberly, Gaur, Abhishek, Cobb, Bryan R, Macaluso, Christine J, Weiss, Jonathan, Seleri, Sheila, and Win, Nikki
- Abstract
Background: A timely and accurate diagnosis of Alzheimer's disease (AD) can optimize treatment outcomes; however, few people are referred to a specialist for reasons that are not well understood. The objective of this study was to evaluate referral to a specialist by a primary care clinician (PCC) or other healthcare provider (HCP) among people diagnosed with cognitive impairment disorders, including AD (CIDiAD). Method: This retrospective cohort study analyzed claims data from the Optum de‐identified Normative Health Information database between 1/1/2016‐31/12/2021 (study period). Adults were required to have ≥2 ICD‐9/10‐CM diagnosis codes for AD from any provider during the study period. The index event was defined as the first CIDiAD diagnosis (Table 1) from a PCC or other HCP before or on the date of their diagnosis during the identification period (1/1/2017‐31/12/2020) (Table 2). Continuous medical enrollment was required in the pre‐ and postindex periods. No diagnoses of CIDiAD in the pre‐index period were allowed. People with a post‐index diagnosis of AD from a specialist comprised the referral cohort. Time to specialist referral was assessed, and characteristics of people who were or were not referred were summarized. Result: A total of 48,525 people with a CIDiAD diagnosis from a PCC or other HCP were included; of these, 13,074 (26.9%) were referred to a specialist. The overall median (IQR) time to first specialist visit was 10.0 (3.2‐20.7) months. Time to first specialist visit was longer for referrals from PCCs compared with those from other HCPs (10.8 [3.8‐21.6] vs 9.2 [2.8‐19.9] months, respectively; P<0.0001). No notable differences in sex, age, race and ethnicity, or geographic region were observed between people who were referred and those who were not (Table 3). Conclusion: The majority of people with CIDiAD were not referred to a specialist. Among people who were referred to a specialist, time to first visit was long. Approval of disease‐modifying therapies may accelerate referral to a specialist and shorten referral times as early diagnosis of AD becomes more important. Further analyses will inform geographic differences in specialist referral patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF